日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. SLC39A6 (Ladiratuzumab vedotin Biosimilar) Recombinant Monoclonal Antibody

SLC39A6 (Ladiratuzumab vedotin Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA621669MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    SLC39A6重組單克隆抗體（Ladiratuzumab vedotin Biosimilar）是一種針對人源溶質(zhì)載體家族39成員6（SLC39A6）的靶向治療性抗體類似物。SLC39A6又稱Zrt和Irt樣蛋白6（ZIP6），是一種鋅離子轉(zhuǎn)運(yùn)蛋白，在多種生理過程中發(fā)揮重要作用，其別名還包括雌激素調(diào)節(jié)蛋白LIV-1、S39A6_HUMAN等。該抗體以重組人SLC39A6蛋白制備，具有高度的人源種屬反應(yīng)性，確保了其在人體研究中的特異性和適用性。 Ladiratuzumab vedotin作為靶向SLC39A6的抗體偶聯(lián)藥物（ADC），通過將單克隆抗體與細(xì)胞毒性藥物vedotin偶聯(lián)，可特異性識別并結(jié)合SLC39A6陽性腫瘤細(xì)胞，實現(xiàn)精準(zhǔn)遞送和釋放細(xì)胞毒性物質(zhì)，從而高效殺傷腫瘤細(xì)胞。目前，相關(guān)臨床研究正聚焦于評估該抗體研發(fā)的藥物在晚期實體瘤患者中的安全性、耐受性及抗腫瘤活性，有望為SLC39A6高表達(dá)腫瘤患者提供新的治療選擇。 在SLC39A6重組單克隆抗體是探究SLC39A6生物學(xué)功能的關(guān)鍵工具。研究人員可利用該抗體進(jìn)行實驗，檢測SLC39A6在不同組織和細(xì)胞系中的表達(dá)水平與定位；通過免疫沉淀等技術(shù)研究其相互作用蛋白，揭示其參與的信號通路機(jī)制；還可構(gòu)建SLC39A6基因敲除或過表達(dá)細(xì)胞模型，結(jié)合抗體干預(yù)實驗，深入探討其在細(xì)胞代謝、信號轉(zhuǎn)導(dǎo)及腫瘤發(fā)生中的分子機(jī)制。此外，該抗體在藥物開發(fā)中也可用于靶點(diǎn)驗證、藥效篩選及生物標(biāo)志物檢測，為基于SLC39A6的新藥研發(fā)提供重要支持。
  • Uniprot No.：
  • 基因名：
  • 別名：
    Estrogen regulated protein LIV 1 6 antibody; Estrogen-regulated protein LIV-1 antibody; LIV 1 antibody; LIV 1 protein, estrogen regulated antibody; S39A6_HUMAN antibody; SLC39A6 antibody; Solute carrier family 39；metal ion transporter, member 6 antibody; solute carrier family 39；zinc transporter, member 6 antibody; Solute carrier family 39 member 6 antibody; Zinc transporter ZIP6 antibody; ZIP 6 antibody; ZIP-6 antibody; Zrt and Irt like protein 6 antibody; Zrt- and Irt-like protein 6 antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human SLC39A6 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    In stock
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點(diǎn)詳情

  • 功能：
    May act as a zinc-influx transporter.
  • 基因功能參考文獻(xiàn)：
    1. ZIP6 deficiency disturbs intracellular Zn2+ homeostasis, leading to increased cell survival in hypoxia and reduced E-cadherin expression, indicating that decreased ZIP6 expression is strongly associated with resistance to hypoxia. PMID: 28833062
    2. SLC39A6 promotes aggressiveness of esophageal carcinoma cells by increasing intracellular levels of zinc, activating phosphatidylinositol 3-kinase signaling, and up-regulating genes that regulate metastasis. PMID: 28209530
    3. Upregulation of SLC39A6 is associated with hepatocellular carcinoma. PMID: 26684241
    4. SLC39A6 may have a tumor promoting role in esophageal carcinoma PMID: 26444413
    5. Knock-down of ZIP6 but not ZIP7 in MIN6 beta cells impaired the protective effects of GLP-1 on fatty acid-induced cell apoptosis, possibly via reduced activation of the p-ERK pathway PMID: 25969539
    6. drug resistance of ovarian cancer cells to trichostatin A may be related to expression of the LIV1 gene PMID: 25420545
    7. Zinc and its transporters, ZIP6 and ZIP10, are required for the breast cancer cells motility stimulated with high glucose level, such as in diabetes. PMID: 24587242
    8. a causative role for ZIP6 in cell motility and migration PMID: 23919497
    9. Down-regulated LIV-1 cells showed significant inhibition of proliferation in vitro and reduction of tumor growth in vivo. Furthermore, E-cadherin expression increased in LIV-1 siRNA expressing Hep-G2. PMID: 23437163
    10. SLC39A6 has an important role in the prognosis of esophageal squamous-cell carcinoma and may be a potential therapeutic target. PMID: 23644492
    11. Some studies correlate LIV-1 expression with a more aggressive cancer phenotype and increased likelihood for metastasis to lymph nodes. In contrast, other evidence suggests this transporter is associated with a more favorable prognosis. [review] PMID: 22852056
    12. The results of this study showed evidence for a positive correlation between LIV1 and ZnT6 insuperior temporal, occipital, and frontal gyri in patient with alzheimer disease. PMID: 22349685
    13. LIV-1 is involved in prostate cancer progression as an intracellular target of growth factor receptor signaling which promoted EMT and cancer metastasis PMID: 22110740
    14. LIV-1 mRNA upregulation is associated with the progression of cervical cancer but not with the development of endometrial carcinoma. PMID: 17959546
    15. The present study identifies LIV1 as a critical mediator responsible for HDACi-induced apoptosis. The effect of LIV1 is, at least in part, mediated by affecting intracellular zinc homeostasis. PMID: 19887557
    16. Zip6 over-expression is not an underlying mechanism initiating breast cancer, but in fact may play a "tumor-constraining" role. PMID: 19852955
    17. Structure-function analysis of LIV-1. PMID: 12839489
    18. data suggest that LIV-1 protein is a promising candidate for a novel marker for breast cancer patients with better outcome PMID: 15986450
    19. regulation of LIV-1 protein in human breast cancer xenografts PMID: 17786585
    20. Hence, our data provide the first evidence that LIV-1 mRNA is overexpressed in cervical cancer in situ and is involved in invasion of cervical cancer cells through targeting MAPK-mediated Snail and Slug expression. PMID: 17825787
    21. LIV-1 may be a regulator of E-cadherin PMID: 18330719
    22. Single nucleotide polymorphism in SLC39A6 gene is associated with acute lymphoblastic leukemia. PMID: 19066393
    23. LIV-1 enhances the aggressive phenotype through the induction of epithelial to mesenchymal transition in human pancreatic carcinoma cells. PMID: 19724917
    24. LIV-1 co-clusters with estrogen receptor alpha in microarray analysis of breast cancer biopsies. PMID: 11911440
    25. Review of LIV-1 and other LZT proteins. PMID: 12659941
    26. LIV-1, a member of the ZIP family of zinc transporters, is an integral plasma membrane protein that transports zinc into cells. PMID: 12839489
    27. LIV-1 is coregulated with estrogen receptor in some breast cancers. PMID: 12960427

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cell membrane; Multi-pass membrane protein.
  • 蛋白家族：
    ZIP transporter (TC 2.A.5) family
  • 組織特異性：
    Highly expressed in the breast, prostate, placenta, kidney, pituitary and corpus callosum. Weakly expressed in heart and intestine. Also highly expressed in cells derived from an adenocarcinoma of the cervix and lung carcinoma.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 18607

    OMIM: 608731

    KEGG: hsa:25800

    STRING: 9606.ENSP00000269187

    UniGene: Hs.79136



×
生命科學(xué)計算平臺